TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03735524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Different exercises will be adopted including: repetition of different movements for ambulation and stair climbing, repetition of crossed patterns of movements for coordination, postural reactions while standing with eyes open and closed and oscillatory boards for balance, strengthening lower limb muscles, and low-intensity and long-duration static stretching of iliopsoas, rectus femoris, hamstrings, triceps surae, and lumbar spinal muscles for muscular flexibility and range of motion. In addition, advanced robotic therapy will be used to standardize rehabilitative treatment and to obtain more objective indexes of motor function. The Lokomat exoskeleton and the Biodex stability system will be used.
Study: NCT01707238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
Study: NCT04205942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Argon Plasma Jet
Description: Cold Plasma (CP) therapy is applied in the first week of treatment on a daily schedule, in the second week CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Sham Cold Plasma (sham-CP) (switched off Electric field, no plasma production, just gas) therapy is applied in the first week of treatment on a daily schedule, in the second week sham-CP is applied every second day. In total, 8 applications are performed with a one day schedule variance.
Study: NCT01097408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7295
Description: Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
Study: NCT01707238

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stenfilcon A
Description: Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
Study: NCT00709865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tonapofylline
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tonapofylline
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tonapofylline
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT03345290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET with a cerebral step
Description: Positron Emission Tomography with a cerebral step before to carry out the standard Position Emission Tomography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Central blood pressure measurement
Description: Central blood pressure measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive tests
Description: Mini Mental State Examination, MMSE, Mini International Neuropsychiatric Interview MINI and Frontal Assessment Batery FAB
Study: NCT01229696

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Placed At Bifurcation
Description: Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter Placed 5cm Above Bifurcation
Description: Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
Study: NCT03284281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tragus stimulator
Description: Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Tragus stimulator
Description: No stimulation will be performed
Study: NCT02907632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Description: Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.~Duration: Until the child completes 40 weeks of post menstrual age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
Study: NCT00602758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with cognitive behavioral therapy
Description: Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing with cognitive behavioral therapy
Description: Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified directly observed therapy
Description: From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
Study: NCT01440257

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group B)
Study: NCT00133549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Saline placebo administered in a volume of 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNU-IMUNE®23
Description: The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNU-IMUNE®23
Description: The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PNU-IMUNE®23
Description: The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nine-valent pneumococcal conjugate (PNCRM9)
Description: Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nine-valent pneumococcal conjugate (PNCRM9)
Description: Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
Study: NCT02204475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir/Elbasvir
Description: Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir
Description: Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron
Description: Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavarin
Description: Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
Study: NCT03642132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy + avelumab followed by avelumab + talazoparib
Description: Chemotherapy Period Paclitaxel Carboplatin Avelumab~Maintenance Period Avelumab Talazoparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by talazoparib maintenance
Description: Chemotherapy Period Paclitaxel Carboplatin~Maintenance Period Talazoparib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy + bevacizumab followed by bevacizumab
Description: Chemotherapy Period Paclitaxel Carboplatin Bevacizumab~Maintenance Period Bevacizumab
Study: NCT03145818

Intervention type: OTHER
Intervention: VD-HCBS
Description: Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease

Intervention type: OTHER
Intervention: VD-HCBS
Description: Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease

Intervention type: OTHER
Intervention: VD-HCBS
Description: Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease

Intervention type: OTHER
Intervention: VD-HCBS
Description: Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
Study: NCT03801031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Topical
Description: Many women treated for gynecologic cancer complain of sexual dysfunction and discomfort. It is thought that topical lidocaine application prior to sexual encounters may have reduced discomfort and improved overall quality of life during and following cancer treatment. The use of the lidocaine solution/placebo is the intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution intervention used to validate the effects of the lidocaine solution usage.
Study: NCT04508218

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplementation powder (Inkospor X-TREME; France)
Description: Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein supplementation powder (Inkospor X-TREME; France)
Description: Protein requirements for burned adults are estimated as 1.5-2.0 g/kg/day. The participants asked to take the calculated serving of whey protein dissolved in 150ml of water two times / day in the morning and in the evening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: After healing of the burn (6 weeks after injury), participants in group A and group C started resisted exercise program with a qualified therapist for 1 hour three times/week on nonconsecutive days over 12 weeks. In addition, aerobic exercises were conducted on the treadmill. Peak oxygen consumption was assessed for all patients by using the exercise test on treadmill before participation in aerobic exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional burn care
Description: ROM exercises, stretching, ADL activities and scar management
Study: NCT00572130

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 1
Description: Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G Dose 2
Description: Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
Study: NCT03615040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSTT1041A
Description: MSTT1041A (RO7187807; formerly made by Amgen \[AMG\] and referred to as AMG 282) is a novel biopharmaceutical that blocks signaling of interleukin (IL)-33, an inflammatory cytokine of the IL-1 family and member of the newly discovered alarmin class of molecules. IL-33 is released from airway epithelial cells in response to allergens, irritants, and infection. IL-33 release can trigger acute exacerbations in both asthma and COPD. MSTT1041A has the ability to block inflammation,prevent exacerbations, and improve lung function and quality of life.~Anti-ST2 is presented as sterile, clear, and colourless to slightly yellow liquid. Each sterile vial is filled with a 1 mL deliverable volume of 70 mg/mL. It is formulated with 15 mM sodium acetate, 9.0% (w/v) sucrose, 0.01% (w/v) polysorbate 20, pH 5.2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Anti-ST2 (MSTT1041A) is formulated with 10 mM sodium acetate, 9.0% (w/v) sucrose, 0.004% (w/v) polysorbate 20, pH 5.2, and is supplied in an identical vial configuration.
Study: NCT02101710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elantan SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elantan SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdur SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdur SR 60 mg
Description: * Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration
Study: NCT00349050

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laboratory pain assessment
Description: Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS.
Study: NCT04430595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4SCAR T cells
Description: Infusion of 4SCAR-GD2, -Her2 and -CD44v6 CAR-T cells
Study: NCT02317744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and bupropion combination

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Study: NCT03549832

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simeprevir
Description: Simeprevir 150 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclatasvir
Description: Daclatasvir 60 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 200 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 200 mg oral pills

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Ombitasvir/paritaprevir/ritonavir oral pills
Study: NCT02269085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.~Phase II Starting Dose: MTD from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.~Phase II Starting Dose: MTD from Phase I.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Calls
Description: Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
Study: NCT04760743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP2001 adjuvanted with alum (RBD 30μg/dose)
Description: Participants will receive intramuscular (IM) injections of NBP2001(RBD 30μg/dose) on Days 0 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP2001 adjuvanted with alum (RBD 50μg/dose)
Description: Participants will receive intramuscular (IM) injections of NBP2001(RBD 50μg/dose) on Days 0 and 28.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Participants will receive intramuscular (IM) injections of Normal saline on Days 0 and 28.
Study: NCT06445452

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Direct SNAP-Ed
Description: Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct SNAP-Ed
Description: Six in-home SNAP-Ed lessons are delivered to participants in the SNAP-Ed arm. Lessons are offered weekly and directed by a bilingual and bicultural community health worker.
Study: NCT03725241

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutathione Supplement
Description: 1000 mg/day Glutathione

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: Crystalline cellulose
Study: NCT02737891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesofensine/Metoprolol
Description: Tesofensine 0.5 mg + Metoprolol 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03399396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation for HPV vaccine
Description: The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation for HPV vaccine
Description: The practice facilitation intervention provides coaching support to pediatric practices to guide them through quality improvement projects to increase HPV vaccination rates.
Study: NCT02857634

Intervention type: DEVICE
Intervention: Cellvizio dual band
Description: Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.